Fecal Calprotectin Monitoring Frequency for UC on Tremfya
Check fecal calprotectin every 6 months in your patient who started Tremfya 4 months ago, as they are in the early post-treatment adjustment phase where closer monitoring is warranted.
Rationale for 6-Month Intervals
The 2023 AGA guidelines provide clear direction for biomarker monitoring in UC patients in symptomatic remission 1. The guidelines recommend interval biomarker monitoring every 6-12 months for patients in symptomatic remission 1. However, your patient's specific situation—being only 4 months into a new biologic therapy—places them in a higher-risk category that justifies the more frequent end of this range.
Why 6 Months is Appropriate Now
- Recent treatment adjustment: Your patient started Tremfya 4 months ago, placing them in the "recently achieved symptomatic remission after treatment adjustment in the preceding 1-3 months" category 1
- Early monitoring phase: At 4 months post-initiation, you're still establishing their treatment response pattern
- Guideline flexibility: The 6-12 month range allows clinical judgment, and earlier therapy initiation warrants closer surveillance 1
Specific Monitoring Strategy
Current Phase (Months 4-12)
- Check calprotectin every 6 months during the first year on Tremfya
- Use fecal calprotectin <50 μg/g as your target in this early post-treatment phase, as this cutoff better detects endoscopic improvement (Mayo Endoscopic Score 0 or 1) compared to the standard <150 μg/g threshold 1
After First Year (If Stable Remission)
- Extend to every 12 months if the patient maintains symptomatic remission with consistently normal calprotectin values
- Continue using the <150 μg/g threshold for routine monitoring in established remission 1
Action Thresholds
If Calprotectin is Elevated (>150 μg/g)
The AGA recommends endoscopic assessment rather than empiric treatment adjustment 1. However, repeat measurement in 3-6 months is a reasonable alternative to avoid unnecessary endoscopy 1. If calprotectin remains elevated on repeat testing, then endoscopy is warranted 1.
If Calprotectin is Normal (<150 μg/g)
- This reliably rules out active inflammation and obviates routine endoscopic assessment 1
- Continue current therapy and maintain monitoring schedule
Important Caveats
Consider more frequent monitoring (every 3-4 months) if:
- Patient develops new symptoms between scheduled checks
- Previous calprotectin was borderline elevated (100-200 μg/g)
- Patient has extensive colitis or prior severe disease
- There's concern about treatment adherence
The BSG 2025 guidelines suggest that calprotectin >200 μg/g should trigger discussion about endoscopy, while values of 100-200 μg/g in an otherwise well patient should prompt retesting within a reasonable timeframe 2.
Practical Considerations
- Combine biomarker monitoring with symptom assessment using a clinical index like the Simple Clinical Colitis Activity Index 1
- Fecal calprotectin is preferred over CRP for UC monitoring, as CRP may be less informative in UC patients, particularly those recently achieving remission 1
- Be aware that calprotectin values can vary significantly within the same day in active disease 3, though this is less relevant in monitoring stable patients
After 12 months of stable remission on Tremfya, you can reasonably extend monitoring intervals to every 12 months, aligning with the upper end of the AGA's recommended range 1.